98%
921
2 minutes
20
Cancer is a disease that can cause abnormal cell growth and can spread throughout the body. It is among the most significant causes of death worldwide, resulting in approx. 10 million deaths annually. Many synthetic anticancer drugs are available, but they often come with side effects and can interact negatively with other medications. Additionally, many chemotherapy drugs used for cancer treatment can develop resistance and harm normal cells, leading to dose-limiting side effects. As a result, finding effective cancer treatments and developing new drugs remains a significant challenge. However, plants are a potent source of natural products with the potential for cancer treatment. These biologically active compounds may be the basis for enhanced or less toxic derivatives. Herbal medicines/phytomedicines, or plant-based drugs, are becoming more popular in treating complicated diseases like cancer due to their effectiveness and are a particularly attractive option due to their affordability, availability, and lack of serious side effects. They have broad applicability and therapeutic efficacy, which has spurred scientific research into their potential as anticancer agents. This review focuses on Paclitaxel (PTX), a plant-based drug derived from Taxus sp., and its ability to treat specific tumors. PTX and its derivatives are effective against various cancer cell lines. Researchers can use this detailed information to develop effective and affordable treatments for cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826257 | PMC |
http://dx.doi.org/10.1186/s40001-024-01657-2 | DOI Listing |
JPEN J Parenter Enteral Nutr
September 2025
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia.
Background: Hospitalized patients may require nutrition support because of inadequate intake or impaired gut function. Enteral nutrition is preferred over parenteral nutrition because of fewer complications and earlier return of gut function. This study describes peripheral parenteral nutrition (PPN) use in an Australian tertiary center, evaluating its indications, incidence of adverse effects, and outcomes without the support of a nutrition support service.
View Article and Find Full Text PDFPulm Ther
September 2025
Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216, Ingelheim am Rhein, Germany.
Introduction: The modification of an inhaler's air flow resistance influences a patient's inhalation flow profile, thereby affecting the exit velocity of an aerosol leaving the Respimat® mouthpiece. A slower inhalation maneuver results in reduced plume velocity and thus a decreased oropharyngeal deposition due to reduced impaction. This could not only lead to fewer unwanted side effects associated with inhaled therapies, but also enhance lung deposition.
View Article and Find Full Text PDFJ Gen Intern Med
September 2025
UCSF Benioff Homelessness and Housing Initiative, University of California, San Francisco, CA, USA.
Background: Older homeless-experienced adults are at higher risk of loneliness than general older adults. Loneliness is associated with multiple adverse health and mental health outcomes. Less is known about factors contributing to loneliness among older adults who experience homelessness.
View Article and Find Full Text PDFAesthetic Plast Surg
September 2025
Department of Plastic Surgery, The First Affiliated Hospital, Jinan University, No. 613 West, Huangpu Avenue, Guangzhou, 510630, Guangdong Province, China.
Background: Microfocused ultrasound (MFU) is a non-invasive technique used for facial rejuvenation, yet there is limited quantitative data on its long-term effects. This study aimed to evaluate the long-term efficacy and safety of MFU for facial rejuvenation. We utilized standardized photography along with advanced skin assessment technologies to analyze the impact of MFU on facial morphology, skin function, and patient satisfaction over a 12-month period.
View Article and Find Full Text PDFThorax
September 2025
Usher Institute, The University of Edinburgh, Edinburgh, UK
Background: The long-acting monoclonal antibody nirsevimab and respiratory syncytial virus (RSV) vaccines became available for prevention of severe RSV-associated disease in 2023. While clinical trials showed good efficacy and safety, their restrictive inclusion criteria, small sample sizes and short follow-up limit generalisability. We aimed to summarise real-world evidence on the effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults.
View Article and Find Full Text PDF